Mark Emberton, MD is the Dean of Medicine at University College London, UK where he also serves as Director of the Partners' Pathway for urological oncology for London Cancer - a provider network serving 4 million people. As Professor of Interventional Oncology at UCL he leads a clinical innovation team that majors in experimental medicine by combining bio-engineering and nanotechnology with early phase trials in men with prostate cancer. He is an active researcher, lectures widely and has published over 200 peer reviewed articles in numerous scientific journals.
He is a pioneer of Focal Therapy of Prostate Cancer using High Frequency Ultrasound (HIFU) waves. Long before the ability to perform real-time FocalyxTx, he introduced cognitive fusion for Biopsy and Treatment of Prostate Cancer with emphasis in Quality of Life measures.